Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
6 days ago
Testosterone treatment may slightly improve sexual functioning and quality of life in men without underlying organic causes of hypogonadism, but it offers little to no benefit for other common symptoms of ageing, according to a study. In addition, long-term efficacy and safety of this therapy remain unknown.
11 Jan 2020
Prevention of glucocorticoid-induced osteoporosis (GIOP) and postmenopausal osteoporosis (PMOP) remains inadequate in patients with rheumatoid arthritis (RA), as shown in a study that evaluated the implementation of the 2003 and 2014 French guidelines on the prevention and treatment of GIOP and the 2012 update of the French guidelines for the treatment of PMOP.

Neurodevelopmental, visual outcomes similar in ROP children with or without IVB treatment

04 Nov 2019

Refractive and visual outcomes, as well as neurodevelopmental outcomes, are similar at mean age of 1.5 years between children with prior history of intravitreal bevacizumab injection (IVB) and premature patients with retinopathy of prematurity (ROP) without treatment, as shown in a study.

However, a possibility exists that a small but clinically significant difference may not have been detected in this study, according to the authors.

This prospective case-control study enrolled three groups of premature patients: children who had no history of ROP (group 0), children with history of ROP without treatment (group 1) and children with ROP who had received a single IVB (0.625 mg; group 2).

Ocular development assessment, including cycloplegic refractometry, axial length, Cardiff acuity, and neurodevelopmental assessment via the Bayley Scales of Infant and Toddler Development, Third Edition were conducted at age 1 to 3 years and compared between groups.

Overall, 148 patients (85 boys and 63 girls; mean age at assessment, 1.49±0.59 years) were included. Gestational age (GA), birth weight and Apgar scores were significantly higher in group 0 patients compared with those in groups 1 and 2.

No significant differences were seen between groups 1 and 2 in terms of demographics or systemic risk factors, except for lower GA in group 2. Patients in groups 1 and 2 had significantly larger cylindrical power than those in group 0.

Group 2 had significantly more myopic spherical equivalent and significantly poorer Cardiff acuity as compared with group 0. Refractive status, axial length or Cardiff acuity were not significantly different between groups 1 and 2.

After adjusting for GA and other systemic risk factors, no significant difference was found in any aspect of neurodevelopment assessment among the three groups. There was also no significant difference in the risks for poor neurodevelopmental outcomes.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
6 days ago
Testosterone treatment may slightly improve sexual functioning and quality of life in men without underlying organic causes of hypogonadism, but it offers little to no benefit for other common symptoms of ageing, according to a study. In addition, long-term efficacy and safety of this therapy remain unknown.
11 Jan 2020
Prevention of glucocorticoid-induced osteoporosis (GIOP) and postmenopausal osteoporosis (PMOP) remains inadequate in patients with rheumatoid arthritis (RA), as shown in a study that evaluated the implementation of the 2003 and 2014 French guidelines on the prevention and treatment of GIOP and the 2012 update of the French guidelines for the treatment of PMOP.